Bio
Todd Wills is a Managing Director in the CAS Services group. He is responsible for shaping the vision and setting the strategic direction for the Custom Services business. Prior to joining CAS, he worked at Emerson Electric where he served in a variety of corporate and operating roles, most recently running their global, data-driven battery monitoring and diagnostics business. Todd holds an MBA from The Ohio State University and a BS in Finance from John Carroll University.
Drug Discovery
AI 药物发现:评估首批进入人体临床试验阶段的 AI 设计候选药物
本篇博客详细介绍了最近发布的 CAS 药物创新指标,该指标基于新分子实体 (NME) 的结构新颖性,能够更好地评估新药的创新性。
Drug Discovery
突破性疗法认定:结构新颖性的真正影响力
了解公司如何利用 CAS 先进的机器学习方法来提高预测准确性、获得突破性技术地位并缩短新药的开发和审查时间。